News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
487,818 Results
Type
Article (8610)
Company Profile (147)
Press Release (479059)
Multimedia
Podcasts (6)
Webinars (8)
Section
Business (167875)
Career Advice (320)
Deals (25905)
Drug Delivery (9)
Drug Development (53637)
Employer Resources (15)
FDA (9883)
Job Trends (8677)
News (240068)
Policy (18065)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (502)
Accelerated approval (25)
ADA (19)
Adcomms (6)
Allergies (102)
Alliances (33500)
ALS (104)
Alzheimer's disease (981)
Antibody-drug conjugate (ADC) (278)
Approvals (10459)
Artificial intelligence (323)
ASCO (162)
Autoimmune disease (207)
Automation (28)
Bankruptcy (264)
Best Places to Work (7021)
BIO (37)
BIOSECURE Act (5)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (95)
Bladder cancer (138)
Brain cancer (29)
Breast cancer (506)
Cancer (3665)
Cardiovascular disease (222)
Career advice (254)
Career pathing (1)
CAR-T (182)
CDC (1)
Celiac Disease (1)
Cell therapy (507)
Cervical cancer (34)
Clinical research (48404)
Collaboration (1264)
Commercialization (2)
Compensation (1423)
Complete response letters (37)
COVID-19 (825)
CRISPR (69)
C-suite (756)
Cystic fibrosis (85)
Data (5650)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (344)
Diagnostics (4185)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (158)
Drug pricing (8)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73553)
Editorial (4)
Employer branding (2)
Employer resources (15)
Events (88189)
Executive appointments (716)
FDA (12492)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (938)
Gene editing (134)
Generative AI (9)
Gene therapy (345)
GLP-1 (301)
Government (974)
Grass and pollen (2)
Guidances (282)
Healthcare (9432)
Hematology (97)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (108)
Immuno-oncology (56)
Indications (155)
Infectious disease (1015)
Inflammatory bowel disease (133)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (250)
Interviews (43)
IPO (12454)
IRA (2)
Job creations (2004)
Job search strategy (244)
JPM (3)
Kidney cancer (16)
Labor market (5)
Layoffs (74)
Legal (5208)
Licensing (5)
Liver cancer (45)
Longevity (15)
Lung cancer (507)
Lymphoma (252)
Machine learning (27)
Management (4)
Manufacturing (534)
Marketing (8)
MASH (119)
Medical device (8679)
Medtech (8815)
Mergers & acquisitions (14479)
Metabolic disorders (708)
mRNA (59)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (226)
Neuropsychiatric disorders (38)
Neuroscience (1834)
NextGen: Class of 2026 (3200)
Non-profit (857)
Now hiring (4)
Obesity (223)
Opinion (13)
Ovarian cancer (160)
Pain (181)
Pancreatic cancer (194)
Parkinson's disease (203)
Partnered (11)
Patents (465)
Patient recruitment (502)
Peanut (31)
People (41613)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15748)
Phase 2 (21667)
Phase 3 (14564)
Pipeline (7050)
Policy (30)
Postmarket research (1580)
Preclinical (6615)
Press Release (34)
Prostate cancer (189)
Psychedelics (8)
Radiopharmaceuticals (189)
Rare diseases (590)
Real estate (3075)
Recruiting (6)
Regulatory (14924)
Reports (19)
Research institute (599)
Resumes & cover letters (48)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (101)
Series A (165)
Series B (121)
Service/supplier (5)
Sickle cell disease (63)
Special edition (2)
Spinal muscular atrophy (89)
Sponsored (6)
Startups (2065)
Stomach cancer (3)
Supply chain (51)
Tariffs (2)
The Weekly (2)
Vaccines (333)
Venture capital (20)
Weight loss (75)
Women's health (77)
Date
Today (3)
Last 7 days (511)
Last 30 days (1439)
Last 365 days (19272)
2026 (11747)
2025 (19540)
2024 (23241)
2023 (26838)
2022 (34992)
2021 (37571)
2020 (33753)
2019 (23509)
2018 (17627)
2017 (18938)
2016 (18110)
2015 (24433)
2014 (21799)
2013 (18241)
2012 (20293)
2011 (20547)
2010 (20405)
Location
Africa (236)
Alabama (72)
Alaska (2)
Arizona (299)
Arkansas (11)
Asia (18336)
Australia (2130)
California (11844)
Canada (3128)
China (540)
Colorado (476)
Connecticut (400)
Delaware (209)
Europe (25425)
Florida (1755)
Georgia (370)
Hawaii (3)
Idaho (46)
Illinois (692)
India (45)
Indiana (314)
Iowa (14)
Japan (409)
Kansas (99)
Kentucky (31)
Louisiana (26)
Maine (25)
Maryland (1198)
Massachusetts (7869)
Michigan (304)
Minnesota (559)
Mississippi (4)
Missouri (79)
Montana (20)
Nebraska (11)
Nevada (115)
New Hampshire (60)
New Jersey (2595)
New Mexico (12)
New York (2792)
North Carolina (1257)
North Dakota (4)
Northern California (5909)
Ohio (273)
Oklahoma (14)
Oregon (16)
Pennsylvania (2278)
Puerto Rico (20)
Rhode Island (30)
South America (411)
South Carolina (76)
South Dakota (1)
Southern California (4902)
Tennessee (116)
Texas (1922)
United States (38588)
Utah (356)
Vermont (1)
Virginia (152)
Washington D.C. (39)
Washington State (915)
West Virginia (1)
Wisconsin (73)
487,818 Results for "latigo biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPO
Latigo, BlossomHill detail IPO plans for pain and cancer push
Latigo Biotherapeutics is looking to raise up to $285.2 million for a non-opioid analgesic, while BlossomHill Therapeutics is eyeing up to $129.1 million in proceeds for its oncology pipeline.
August 4, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering
August 7, 2026
·
4 min read
Press Releases
Latigo Biotherapeutics Appoints Todd Smith to its Board of Directors
July 8, 2026
·
2 min read
Press Releases
Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain
July 29, 2026
·
4 min read
Press Releases
Latigo Biotherapeutics Appoints Sara M. Bonstein to its Board of Directors and as Audit Committee Chair
April 8, 2026
·
3 min read
Press Releases
Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer and Chief Business Officer
March 3, 2026
·
3 min read
Biotech Beach
Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines
Latigo Biotherapeutics Inc., a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, announced its emergence from stealth with a $135 million Series A financing.
February 14, 2024
·
3 min read
Press Releases
Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics
March 17, 2025
·
3 min read
Press Releases
Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair
November 19, 2024
·
3 min read
Press Releases
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 7, 2026
·
11 min read
1 of 48,782
Next
